The sympathetic nervous system is central for the neurohumoral regulation of the
cardiovascular system and is largely involved in many cardiovascular diseases affecting …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

Background—Nebivolol and carvedilol are third-generation β-adrenoreceptor antagonists,
which unlike classic β-blockers, have additional endothelium-dependent vasodilating …

Background—The therapeutic effects of nonspecific β-blockers are limited by
vasoconstriction, thus justifying the interest in molecules with ancillary vasodilating …

β-Adrenoceptor blocking agents (β-blockers) have been established as therapeutics for
treatment of patients with hypertension, ischemic heart diseases, chronic heart failure …

Objectives: The present study was to assess whether nebivolol could activate β3-adrenergic
receptors (ARs) in the human heart. Background: Nebivolol is a third-generation β-blocker …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Nebivolol is a racemic combination of d‐nebivolol (+ SRRR nebivolol) and l‐nebivolol (–
RSSS nebivolol) that differs chemically from other β‐blockers, with an absolutely …

Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes
vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol …

Beta‐blockers are well‐established therapeutic agents in the treatment of hypertension and
cardiovascular disease. However, these agents are highly heterogeneous. Beta‐blockers …